Pharming Group Reports Q3 2026 Revenue Above Market Expectations
Pharming Group announced preliminary, unaudited revenue for the three months ended September 30, 2026, above market expectations.
Story updates
05:07:30 AM UTC
SquawkNews
Pharming Group N.V. issued preliminary, unaudited Q3 2026 revenue of about $117.6M, up ~21% YoY, with total operating expenses about $74.6M, below analyst consensus. 2026 revenue guidance narrowed to $380M—$390M and opex lowered to $310M—$315M.Material DetailsContext by AI AnalystThis is a mid-cycl…
05:12:22 AM UTC
SquawkNews
Pharming Group N.V. EURONEXT:PHARM
Leiden, the Netherlands, October 22, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announces preliminary, unaudited revenue and select financial information for the three months ended September 30…